Cytek BiosciencesCTKB
About: Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Employees: 663
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
41% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 22
5% more funds holding
Funds holding: 151 [Q4 2024] → 159 (+8) [Q1 2025]
0.51% more ownership
Funds ownership: 59.95% [Q4 2024] → 60.47% (+0.51%) [Q1 2025]
21% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 63
38% less capital invested
Capital invested by funds: $501M [Q4 2024] → $311M (-$191M) [Q1 2025]
91% less call options, than puts
Call options by funds: $2K | Put options by funds: $22K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Goldman Sachs Matthew Sykes | 17%upside $3 | Sell Maintained | 12 May 2025 |
Stephens & Co. Mason Carrico | 133%upside $6 | Overweight Reiterated | 19 Mar 2025 |
Piper Sandler David Westenberg | 211%upside $8 | Overweight Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 6 articles about CTKB published over the past 30 days









